$2.65
(3.97%)
0.19%
Create an alert
Stocks and Shares ISAAnaptysBio, Inc. is a royalty management company. The Company manages the financial collaborations for Jemperli with GlaxoSmithKline (GSK) and imsidolimab with Vanda Pharmaceuticals Inc. (Vanda). The Company's financial collaboration with GSK is focused upon the development and commercialization of Anaptys-discovered Jemperli (dostarlimab), a PD-1 antagonist, approved for endometrial cancer and dMMR pan tumors, and is being studied in rectal cancer, colon cancer and head and neck squamous cell carcinoma. The Company's financial collaboration with Vanda is focused upon the development and commercialization of Anaptys-discovered imsidolimab, an IL-36R antagonist, which is being developed for generalized pustular psoriasis (GPP).
Company Information
About this company
Key people
John A. Orwin
Non-Executive Independent Chairman of the Board
Daniel R. Faga
President, Chief Executive Officer, Director
Susannah Gray
Director
Oleg Nodelman
Independent Director
Hollings C. Renton
Independent Director
John P. Schmid
Independent Director
Click to see more
Key facts
- Shares in issue29.10m
- EPICANAB
- ISINUS0327241065
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$1.94bn
- Employees104
- ExchangeNASDAQ
- IndexTR Equity United States Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.